"[1] The FTC's expanding focus on the role of PBMs and manufacturer rebating practices.... [2] FTC's New Policy Statement on Section 5 of the FTC Act signals increased risks of investigation and enforcement.... [3] Congress authorizes Medicare price 'negotiation,' but future legislative efforts are uncertain.... [4] Key aspects of the federal 340B program continue to be litigated.... [5] State focus on drug pricing likely to continue."  MORE >>